Lilly's mGlu2/3 Agonist Fails In Phase II For Schizophrenia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neither Lilly's novel mGlu2/3 molecule nor its comparator, olanzapine, was more effective than placebo in treating acute schizophrenia in a Phase II study, highlighting the problems inherent in clinical trials for the indication